Related Experiment Video
Updated: Aug 30, 2025
09:01
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
3.2K
Phase-Transitional Bismuth-Based Metals enable Rapid Embolotherapy, Hyperthermia, and Biomedical Imaging.
Minghui Duan1,2, Xiyu Zhu1, Linlin Fan3
1Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 100084, China.
Advanced Materials (Deerfield Beach, Fla.)
|August 26, 2022
Summary
A new bismuth-based liquid agent offers advanced embolization, thermotherapy, and imaging for tumors. This innovative material enhances treatment efficacy and provides clear visualization for better patient outcomes.
Area of Science:
- Biomedical Engineering
- Materials Science
- Oncology
Background:
- Conventional embolic agents have limitations including fabrication challenges, precipitation issues, poor visibility, and lack of integrated functions, leading to suboptimal embolization efficacy.
- There is a need for advanced embolic agents that overcome these limitations and offer enhanced therapeutic and diagnostic capabilities.
Purpose of the Study:
- To develop and evaluate a multifunctional bismuth (Bi)-based liquid embolic agent for simultaneous embolotherapy, thermotherapy, and high-contrast biomedical imaging.
- To assess the efficacy, biocompatibility, and theranostic potential of the novel Bi-based agent in tumor treatment.
Main Methods:
- Fabrication of a bismuth (Bi)-based liquid embolic agent with a suitable melting point and metallic properties.
- In vivo evaluation of the agent's embolization efficiency, biocompatibility, and therapeutic effects in tumor models.
- Assessment of multimodal imaging capabilities using computed tomography (CT), magnetic resonance imaging (MRI), and thermography.
Main Results:
- The Bi-based liquid embolic agent demonstrated rapid liquid-solid phase transition, enabling effective arteriovenous embolization.
- In vivo studies showed excellent embolization efficiency, favorable biocompatibility, and significant tumor regression.
- The agent facilitated clear multimodal imaging (CT, MRI, thermography) for tracking and combined therapy with thermotherapy led to complete tumor eradication.
Conclusions:
- The developed bismuth-based liquid embolic agent offers a versatile platform for simultaneous embolotherapy, thermotherapy, and multimodal imaging.
- This innovative agent overcomes limitations of conventional embolic materials, providing improved therapeutic efficacy and diagnostic capabilities for tumor treatment.
- The study presents a promising theranostic modality for embolization and potential future applications in oncology.
